Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus | Zendy

Christine M. Nguyen | Zendy; Margaret Mendes | Zendy; Shirley M. Tsunoda | Zendy; D. Joseph | Zendy

Open Access

Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus

Author(s) -

Christine M. Nguyen,

Margaret Mendes,

Shirley M. Tsunoda,

D. Joseph

Publication year - 2011

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1207

Subject(s) - ribavirin , interleukin 28b , medicine , pegylated interferon , hepatocellular carcinoma , hepatitis c virus , cirrhosis , genotype , hepatitis c , liver disease , interferon , virology , immunology , virus , gastroenterology , gene , biology , biochemistry

Hepatitis C virus (HCV) is a bloodborne infection that is one of the leading causes of liver disease. If left untreated, HCV can lead to cirrhosis, hepatocellular carcinoma, and death. The current standard of care for HCV is a combination of pegylated-interferon (peg-IFN) and ribavirin (RBV) in which the goal of treatment is to decrease complications and death due to HCV. HCV displays genetic polymorphism, where patients with HCV genotype 1 may have higher viral replication rates and are less likely to respond to treatment. These patients require a longer duration of treatment and a higher RBV dose. The interleukin (IL) 28B genotype test is associated with a sustained virologic response (SVR), defined as an undetectable HCV ribonucleic acid (RNA) upon completion of treatment and 24 weeks thereafter.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research